Will pharmaceutical companies manufacturing the allopathic treatment of MERS, ‘Ribavirin,’ be able to take the advantage?
While continuous death of MERS (Middle East Respiratory Syndrome) patients has suddenly increased interested in the treatment, the industry is paying attention to the manufacturing pharmaceutical companies of Ribavirin which is used as its allopathic treatment.
According to the Ministry of Food ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
